Future prospectives for the management of chronic hepatitis B

Table 1 Baseline factors influencing likelihood of response to antiviral therapy

Treatment	Increased likelihood of response	Decreased likelihood of response
(PEG) interferon	Baseline ALT > 2 ULN[28,145,146]	Baseline ALAT < 2 ULN[28,145,146]
	Baseline HBV DNA < 109 c/mL[4,28]	Baseline HBV DNA > 109 c/mL[4,28]
	Genotype A or B	Genotype C or D
	Longer treatment duration[33-35,147]
Nucleoside/nucleotide analogues	Baseline serum aminotransferases > 2 ULN[148,149]	Baseline serum aminotransferases < 2[148,149]
	Baseline HBV DNA < 109 c/mL[148]	Baseline HBV DNA > 109 c/mL[148]

ULN: Upper limit of normal; c/p = copies/mL.